Last reviewed · How we verify
Tussionex Pennkinetic (CHLORPHENIRAMINE MALEATE)
Tussionex Pennkinetic (Chlorpheniramine Maleate) is a small molecule histamine-1 receptor antagonist developed by Bayer Healthcare LLC. It targets the histamine H1 receptor to treat various allergic conditions, including allergic conjunctivitis, rhinitis, and skin itching. Originally approved by the FDA in 1950, it is now off-patent with 26 generic manufacturers. The drug has a half-life of 22 hours and bioavailability of 41%. It is used to alleviate symptoms such as nasal congestion, discharge, and itching.
At a glance
| Generic name | CHLORPHENIRAMINE MALEATE |
|---|---|
| Sponsor | Bayer |
| Drug class | Histamine-1 Receptor Antagonist |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Dermatographic urticaria
- Influenza-like symptoms
- Itching of skin
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Urticaria
- Vasomotor rhinitis
Common side effects
- Nausea
- Vomiting
- Sedation
- Drowsiness
- Mental clouding
- Lethargy
- Impairment of mental and physical performance
- Dizziness
- Mood changes
- Constipation
- Anxiety
- Fear
Serious adverse events
- Death
- Respiratory depression
- Fatal respiratory depression
- Urinary retention
- Ureteral spasm
- Spasm of vesical sphincters
- Tightness of the chest
Key clinical trials
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection (PHASE2)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) (PHASE1)
- Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tussionex Pennkinetic CI brief — competitive landscape report
- Tussionex Pennkinetic updates RSS · CI watch RSS
- Bayer portfolio CI